Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Why boosting production of Venezuela's 'very dense, very sloppy' oil could harm the environment - 2Game theory explains why reasonable parents make vaccine choices that fuel outbreaks
- 3Drones, physics and rats: Studies show how the people of Rapa Nui made and moved the giant statues – and what caused the island’s deforestation
- 4Geminid meteors streak under green sky | Space photo of the day for Dec. 19, 2025
- 5Kiefer Sutherland arrested after allegedly assaulting a ride-share driver in L.A.
- Flu cases are rising with a strain that makes older people sicker
- 'Crammed into a cell with vermin at New Year'
- Outside Lovers' Decision: Favored Climbing Rucksacks
- Allow Innovative Progressions To have a Tremendous Effect
- They died 'doing what they loved': The stories of workers in their 80s who died on the job
- Washington resident is infected with a different type of bird flu
- 10 Fundamental Tips and Deceives to Lift Your Cell phone's Exhibition
- 5 Family SUVs for 2024: Which One Accommodates Your Family's Needs\uff1f
- Top Breakfast Food: What's Your Morning Enjoyment?
